By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) has been beneath the management of a brand new CEO for simply over a 12 months, with Mr. Hashad not too long ago issuing a letter to shareholders marking the milestone. We now have been telling buyers in regards to the nice … Read more
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Enterprise Replace Reaches Settlement with European Medicines Company on Second Confirmatory Trial for HyBryte On April 3, 2024, Soligenix, Inc. (NASDAQ:SNGX) introduced it has reached settlement with the European Medicines Company (EMA) on the important thing design parts for a confirmatory Part 3 trial … Read more
By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Enterprise Replace Replace on IMNN-101 Imunon, Inc. (NASDAQ:IMNN) is growing IMNN-101, which is a COVID-19 seasonal vaccine booster based mostly on the corporate’s PlaCCine know-how. It’s a DNA vaccine that addresses plenty of limitations of present vaccines, together with the sturdiness of antigen expression, … Read more
By David Bautz, PhD NASDAQ:CRVO READ THE FULL CRVO RESEARCH REPORT Enterprise Replace Biomarker Knowledge Introduced at AD/PD 2024 On March 5, 2024, CervoMed Inc. (NASDAQ:CRVO) introduced the presentation of biomarker knowledge from the AscenD-LB Part 2a trial of neflamapimod in sufferers with dementia with Lewy our bodies (DLB) was featured in a poster presentation … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT For the total 12 months 2023, complete revenues elevated roughly 5.0% to $36.3 million. Complete product gross sales had been $31.1 million, a rise of 6.0% from 2022. 2022 gross sales benefitted from $0.7 million in different non-CytoSorb gross sales and $0.3 million in … Read more
